Eli Lilly and Company (SWX:LLY)
Switzerland · Delayed Price · Currency is CHF | Market Cap | 519.75B |
| Revenue (ttm) | 42.36B |
| Net Income (ttm) | 10.97B |
| Shares Out | n/a |
| EPS (ttm) | 12.16 |
| PE Ratio | 47.36 |
| Forward PE | 25.80 |
| Dividend | 4.98 (0.86%) |
| Ex-Dividend Date | Aug 15, 2025 |
| Volume | n/a |
| Average Volume | 2 |
| Open | n/a |
| Previous Close | 580.00 |
| Day's Range | n/a |
| 52-Week Range | 538.92 - 805.00 |
| Beta | 0.33 |
| RSI | 39.87 |
| Earnings Date | Oct 30, 2025 |
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Ja... [Read more]
Financial Performance
In 2024, Eli Lilly and Company's revenue was $45.04 billion, an increase of 32.00% compared to the previous year's $34.12 billion. Earnings were $10.59 billion, an increase of 102.08%.
Financial numbers in USD Financial StatementsNews
Eli Lilly: Strong Buy On Sustained Growth, Expanding Moat, And Pipeline Depth
Eli Lilly's valuation has compressed significantly from last year's highs, despite fundamentals improving faster than its share price. Industry-leading incretin treatments (Mounjaro, Zepbound) are dri...
LLY Stock Set For A 20% Breakout?
Eli Lilly stock (NYSE: LLY) should be on your radar. Here's why – it is presently trading within the support range ($688 – $761), price points from which it has previously bounced significantly.
Novo, Lilly Weight-Loss Drugs May Help Alzheimer's Patients. What It Means for the Stocks.
The blockbuster medications could open a new frontier for the pharma giants.
Pharma tariffs 'not a huge risk' for domestic companies, says Mizuho's Jared Holz
CNBC's “Fast Money” team discusses the potential impact of pharmaceutical tariffs with Jared Holz, healthcare equity strategist at Mizuho.
Many pharma companies already made U.S. investment promises, says Citi's Geoff Meacham
CNBC's “Closing Bell Overtime” team discusses President Trump's plan to impose a 100% tariff on “all any branded or patented Pharmaceutical Product” entering the U.S. with Geoff Meacham of Citi Resear...
A New Prescription For Pain: Understanding Trump's 100% Pharma Tariff
Novo Nordisk, Sanofi, and AstraZeneca face the largest dollar exposure to President Trump's new 100% tariff on imported branded drugs. NVO's heavy reliance on U.S. sales and imported GLP-1 products pu...
Pharma tariffs still have a lot of questions outstanding, says Bernstein's Courtney Breen
Courtney Breen, Bernstein senior analyst, joins 'The Exchange' to discuss the companies exempt from pharma tariffs, the country's with existing trade deals and much more.
Portal Innovations' John Flavin: Tariffs on pharma could raise costs and delay drug access
John Flavin, Portal Innovations founder and CEO, joins CNBC's 'Squawk on the Street' to discuss the Trump administration's proposed pharmaceutical tariffs, the impact on biotech startups and clinical ...
Lilly opens newest Gateway Labs site in San Diego to boost local biotechnology ecosystem
New 82,514 square foot facility will accommodate up to 15 biotech companies to fuel next-generation medicines Gateway Labs model provides flexible lab space and tailored scientific engagement to supp...
Eli Lilly, Pfizer Stocks Rise After Trump's 100% Pharma Tariff Threat. Here's Why.
Trump's threat of a 100% tariff on imported branded or patented drugs sounds dramatic, yet, pharma stocks were mostly in the green as the past few months have already seen a flurry of companies announ...
Lilly's Kisunla (donanemab) receives marketing authorization by European Commission for the treatment of early symptomatic Alzheimer's disease
Approved for earliest symptomatic stages of disease, demonstrating significant slowing of cognitive and functional decline Only therapy with evidence to support completing course of treatment once amy...
US FDA approves Eli Lilly's therapy for metastatic breast cancer
Eli Lilly said on Thursday that the U.S. Food and Drug Administration has approved its therapy for the treatment of metastatic breast cancer in patients whose disease progressed after at least one lin...
U.S. FDA approves Inluriyo (imlunestrant) for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer
An estimated 50% of patients with ER+, HER2– metastatic breast cancer will develop an ESR1 mutation during or after exposure to an aromatase inhibitor In the Phase 3 EMBER-3 trial, Inluriyo monotherap...
Eli Lilly and Company (LLY) Presents at Bernstein 2nd Annual Global Healthcare Conference Transcript
Eli Lilly and Company (NYSE:LLY) Bernstein 2nd Annual Global Healthcare Conference September 25, 2025 8:00 AM EDT Company Participants Lucas Montarce - Executive VP & CFO Mike Czapar - Director of In...
Eli Lilly: Buying The Dip With Confidence
Eli Lilly (LLY) remains a strong growth company, driven by leadership in the booming GLP-1 and diabetes drug markets despite recent share price weakness. LLY's aggressive investments in manufacturing,...
Eli Lilly halts trial of experimental weight-loss drug
Eli Lilly has halted a study of an experimental drug, which is designed to prevent obesity patients from losing too much muscle, due to strategic business reasons, according to a U.S. registry of clin...
Lilly plans to launch its experimental weight-loss pill in India, exec says
Eli Lilly plans to bring its experimental oral weight-loss drug orforpligron in India as it sees scope for such products in the world's most populous nation, a senior executive said on Thursday.
The Big 3: AVGO, LLY, GS
@Theotrade's Don Kaufman is back on Big 3 — and is bearish on all of today's stocks. He points to exuberant A.I.
IWF, LLY, V, ORCL: Large Inflows Detected at ETF
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Russell 1000 Growth ETF (Symbol: IWF) where we have detected a...
Eli Lilly (LLY) CEO Criticizes UK Drug Pricing Approach
Eli Lilly (LLY) CEO Criticizes UK Drug Pricing Approach
The Zacks Analyst Blog Highlights Apple, Eli Lilly, Chevron and Monarch Cement
Apple, Eli Lilly, Chevron, and Monarch Cement show mixed performance, with growth in services, strong drug demand and strategic acquisitions.
Eli Lilly's boss calls UK the 'worst' European country for drug prices
Eli Lilly Chief Executive Dave Ricks said Britain was "probably the worst country in Europe" for drug prices in an interview with the Financial Times, intensifying pressure on the government to improv...
UK is ‘worst country in Europe’ for drug prices, says Mounjaro maker
Eli Lilly CEO says Britain’s strict regime means it could miss out on new drugs being rolled out unless it pays more Business live – latest updates The chief executive of the pharmaceutical company El...
Eli Lilly calls UK ‘worst country in Europe’ for drug prices; gold nears record high - business live
Spot gold trading just below Monday’s fresh record high Good morning, and welcome to our rolling coverage of business, the financial markets and the world economy. The boss of Eli Lilly has called the...
Eli Lilly To Build $6.5 Bln Manufacturing Plant In Texas For Obesity Pill Production
(RTTNews) - Eli Lilly And Co. (LLY) announced on Tuesday that it will spend $6.5 billion to construct a manufacturing plant in Houston, Texas, with the goal of increasing production of its pipeline of...